The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care ...

MAD World Summit 2026 has secured official accreditation from The CPD Group, strengthening its position as a must-attend ...

AbbVie has announced results from the ongoing phase 3 Viti-Up-1 and Viti-Up-2 studies of Rinvoq (upadacitinib; 15mg once ...

Understanding how AI decisions are made, who owns the outcomes and how accountability travels across partners and platforms ...

Over the past decades, advances in information technology have fundamentally transformed the management of chronic diseases, ...

In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they ...

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment ...

Logistical challenges are not new in clinical research, from the high cost of developing new therapies to complexities in ...

Beam Therapeutics has appointed Eric Foster as Chief Commercial Officer (CCO). Foster will lead Beam’s commercial organisation and strategy as the company advances multiple product candidates across ...

Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of exacerbation history AstraZeneca’s fixed-dose triple-combination Trixeo ...

Roche and Dualitas Therapeutics, a biotechnology company developing next-generation bispecific antibody therapies for immunology and inflammation (I&I) diseases, have announced a research ...

Chiesi Group has appointed David Khougazian as Group Chief Executive Officer (CEO). Khougazian joins Chiesi following an international career spanning more than 25 years across the global healthcare ...